Based on a mean baseline body weight of 248 lb. for Wegovy ® injection 7.2 mg and placebo groups, and 257 lb. for the Wegovy ® 2.4 mg group. * Based on the efficacy estimand: estimated efficacy in an ...

Data from the phase 3b STEP UP trial demonstrate that the 7.2 mg semaglutide dose provides superior weight reduction compared ...

In his complaint, Michael Wade Nance said his veins were so severely compromised that they were likely to blow and cause him ...

Early data from the first phase III trial of Lilly’s triple agonist show reductions in weight and HbA1c for patients with type 2 diabetes.

Is it possible to train the body to resist seasonal allergies? That’s the hope promised by a new line of immunotherapy reviving an old treatment.

Rhythm Pharma (RYTM) surges on IMCIVREE sales growth and TRANSCEND data ahead of the March 20 FDA PDUFA decision—see risks, ...

Dianthus Therapeutics (NASDAQ:DNTH) said it has made an “early go” decision to continue its CAPTIVATE Phase 3 trial ...

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and ...

Wegovy is a Food and Drug Administration-approved weight loss medication for people with obesity or those who are overweight with weight-related health conditions. In recent years, interest in ...

Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A ...

Zealand Pharma’s shares fell 32% in early morning trading Friday after its Roche-partnered asset petrelintide failed to meet investor expectations in a mid-stage clinical trial.